Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer

Clinical Pharmacokinetics

Volumn 34, Issue 5, 1998, Pages 405-417

  Mahler, Ch ^a   Verhelst, J ^a   Denis, L ^a  

^a AZ Middelheim ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; ESTROGEN; FLUTAMIDE; GONADORELIN DERIVATIVE; GONADOTROPIN; GOSERELIN; NILUTAMIDE; TESTOSTERONE;

AROMATIZATION; CANCER SURVIVAL; CARDIOMYOPATHY; CASTRATION; CAUSE OF DEATH; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; GASTROINTESTINAL DISEASE; GONADOTROPIN RELEASE; GYNECOMASTIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; LIBIDO; LIVER DISEASE; LIVER TOXICITY; MALE; MASTALGIA; META ANALYSIS; MIGRAINE; NAUSEA; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SEXUAL FUNCTION; SIDE EFFECT; TESTOSTERONE SYNTHESIS; THROMBOEMBOLISM;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS; CYPROTERONE; FLUTAMIDE; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; MALE; PROSTATIC NEOPLASMS;

EID: 0031947670     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834050-00005     Document Type: Review

References (66)

1. Dorfman RI. Anti-androgenic substances. In: Dorfman RI, editor. Methods in hormone research. Vol II. New York: Academic Press, 1962: 315-23
2. Labrie F, Dupont A, Bélanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 1983; 4: 579-94
3. Boccon-Gibod L, Laudat MH, Dugue MA, et al. Cyproterone acetate led-in prevents initial rise of serum testosterone induced by GNRH analogs in the treatment of metastatic carcinoma of the prostate. Eur Urol 1986; 12: 400-2
4. Migliari R, Muscas G, Usai E. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer. J Urology 1992; 148 (2 Pt 1): 338-41
5. McLeod DG, Kolvenberg GJ. Defining the role of antiandrogens in the treatment of prostate cancer. Urology 1996; 47 Suppl. 1A: 85-9
6. Mahler C, Akaza H, Boccardo F, et al. Secondary hormonal treatment. Proceedings of First International Consultation on Prostate Cancer; 1996 Jun 20-22; Monaco
7. Neuman F, Töpert M. Pharmacology of antiandrogens. J Steroid Biochem 1986; 25 (5B): 885-95
8. Schröder FH. Cyproterone acetate: mechanism of action and clincial effectiveness in prostate cancer treatment. Cancer 1993; 72: 3810-5
9. Knuth UA, Hano R, Nieschlag E. Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in men. J Clin Endocrinol Metab 1984; 59: 963-9
10. de Voogt HJ, Smith PH, Pavone-Macaluso M, et al. Cardiovascular side-effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from EORTC trials 30761 and 30762. J Urol 1986; 135: 303-7
11. Neumann F, Jacobi GH. Antiandrogens in tumour therapy. Clin Oncol 1982; 1: 233-44
12. Jacobi GH, Altwein JE, Kurth KH, et al. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase II randomised trial. Br J Urol 1980; 52: 208-15
13. Pavone-Macalusco M, de Voogt HJ, Vigginao G, et al. Comparison of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a randomized phase II trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986; 136: 624-31
14. Moffat LEF. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990; 18 Suppl. 3: 26-7
15. Robinson MRG, Hetherington J. The EORTC studies: is there an optimal endocrine management for M1 prostatic cancer? World J Urol 1986; 4: 171-5
16. de Voogt HJ, Klijn GM, Studer U. et al. Orchidectomy versus buserelin in combination with cyproterone acetate for 2 weeks or continuously, in the treatment of metastatic prostate cancer. Preliminary results of EORTC trial 30843. J Steroid Biochem Molec Biol 1990; 37: 965-9
17. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346 (8970): 265-9
18. Klijn JGM, de Voogt HJ, Schröder FH, et al. Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma. Lancet 1985: II: 493
19. Katchen B, Buxbaum S. Dispostion of a new, nonsteroid antiandrogen, alpha, alpha, alpha trifluoro-2-methyl-4′-nitro-m-propionotoluidide (flutamide) in men following a single oral 200mg dose. J Clin Endocrinol Metab 1975; 41: 373-9
20. Callaway A, Bruchowsky N, Rennie PS, et al. Mechanisms of action of androgens and antiandrogens on translocation of cytoplasmatic androgen receptor and nuclear abundance of dihydrotestosterone. Prostate 1982; 3: 599-603
21. Wysowski DK, Freiman JP, Tourtelot JB, et al. Fatal and non-fatal hepatotoxicity with flutamide. Ann Intern Med 1993; 118 (11): 860-4
22. Sogani PC, Vagaiwala MR, Whitmore WF Jr. Experience with flutamide in patients with advanced prostatic cancer withour prior endocrine therapy. Cancer 1984; 54: 744
23. Prout Gr Jr, Keating MA, Griffin PP, et al. Long-term experience with flutamide in patients with prostatic carcinoma. Urology 1989; 34: 37-45
24. Whitmore WF Jr. Natural history and staging of prostate cancer. Urol Clin North Am 1984; 11: 209-20
25. Labric F, Dupont A, Bélanger A. A complete androgen blockade for the treatment of prostate cancer. In: Pe Vita VT, Hellman S, Rosenberg SA, editors. Important advances in oncology. Philadelphia: JB Lippincott, 1985; 193-217
26. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24
27. Denis L, Carneiro de Moura JL, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchiedectomy: a phase III EORTC Trial (30853). Urology 1993; 42: 119-30
28. Labrie F, Dupont A, Cusan L, et al. Combination therapy with flutamide: the therapy of choice from early to advanced stages of prostate cancer. In: Denis L, editor. Antiandrogens in prostate cancer. Berlin: Springer-Verlag, 1996: 63-71
29. Narayan P, Lowe BA, Carroll PR, et al. Neoadjuvant hormonal therapy and radical prostatectomy tor clinical stage C carcinoma of the prostate. Br J Urol 1994; 73 (5): 544-8
30. Cher ML, Shinohara K, Breslin S, et al. High failure rale associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Br J Urol 1995; 75 (6): 771-7
31. Pilepich MV, Krall JM, al Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45 (4): 616-23
32. Soloway MS, Sharifi R, Wajsman Z, et al. Randomized prospective study comparing prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 prostate cancer. The Lupron depot neoadjuvant prostate cancer study group. J Urol 1995; 154: 424-8
33. Vaillancourt L, Ttu B, Fradet Y, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Path 1996; 20 (1): 86-93
34. Dupont A, Gomez JL, Cusan L, et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150: 908-13
35. Small EJ, Scrinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients wilh advanced prostate cancer. Cancer 1995; 76: 1428-34
36. McLeod DG, Benson RC Jr, Eisenberger MA, et al. The use of flutamide in hormone-resistant metastatic prostate cancer. Cancer 1993; 72 Suppl.: 3870-3
37. Ojasoo T, Nilutamide. Drugs Future 1987; 12: 763-70
38. Decensi A, Torrisi R, Marroni P, et al. Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion. Prostate 1994; 24 (1): 17-23
39. Harnois C, Malenfant M, Dupont A, et al. Ocular toxicity of anandron in patients treated for prostatic cancer. Br J Ophthalmol 1986; 70: 471-3
40. Gomez JL, Dupont A, Cusan L, et al. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report. Am J Med 1992; 92: 563-6
41. Beland G, Elhilali M, Fradet Y, et al. Total androgen ablation: Canadian experience. Urol Clin North Am 1991; 18: 75-82
42. Pfitzenmeyer P, Foucher P, Piard F. et al. Nilutamide pneumonitis: a report on 8 patients. Thorax 1992; 47: 622-7
43. Moorjani S, Dupont A, Labrie F, et al. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism 1987; 36: 244-50
44. Decensi AU, Boccardo F, Guarneri D, et al. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991; 146: 377-81
45. Bertagna C, de Gery A, Hucher M, et al. Efficacy of the combination of Anandron (nilutamide) with orchidectomy in metastatic cancer. A meta-analysis of seven randomized double-blind trials (1191 patients). Br J Urol 1944; 73 (4): 396-402
46. Knönagel H, Bolle JF, Hering F, et al. Die Therapie des metastasierten Prostatakarzinoms durch Orchicktomie plus Anandron versus Orchiektomie plus Placebo. Erste Ergebnisse einer randomisierten Multizenterstudie. Helv Chir Acta 1989; (56): 343-5
47. Brisset JM. Nilutamide (AnandronR) in prostate cancer: Review of four clinical trials. In: Khoury S, Chatelain C, Denis L, editors. Urology prostate cancer. Paris: Fiis et RGP, 1990: 381-9
48. Namer M, Adenis L, Couette J, et al. Orchiectomy associated with Anandron (RU 23908) or placebo in the treatment of stage D prostatic cancer: preliminary results of a randomised double blind French Cooperative Study. J Endocr Invest 1987; 10 Suppl. 2: 50-6
49. Janknegt RA, Abbou CC, Bartoletti R, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in u multinational double-blind randomized trial. J Urol 1993; 149: 77-83
50. Akaza H, Aso Y, Niijima T, et al. Clinical study of RU23908 (nilutamide) in prostatic cancer. Hinyokika Kiyo 1991; 37: 407-20
51. Le Duc A, Arvis G, Ballanger R, et al. Comparaison de l'efficacité du nilutamide (Anandron) à un placebo sur les douleurs des métastases osseuses de cancer de la prostate. Prog Urol 1992; Suppl. 2: 24-30
52. Kuhn J-M, Billebaud T, Navratil H, et al. Prevention of the transient adverse effects of a gonadotrophin-releasing hormone analogue (buserelin) in metastatic prostate carcinoma by administration of an antiandrogen nilutamide. N Engl J Med 1989; 321: 413-8
53. Navratil H. Preliminary clinical evaluation of leuprolin acetate depot injection in France, in the management of prostatic cancer. J Int Med Res 1990; Suppl. 1: 69-73
54. Migliari R, Scarpa RM, Campus G, et al. Evaluation of efficacy and tolerability of nilutamide and buserilin in the treatment of advance prostate cancer. Arch Ital Urol Androl 1991; 63: 147-53
55. Crawford ED, Smith Jr, Soloway MS, et al. Treatment of stage D2 prostatic cancer with leuprolide and Anandron compared to leuprolide and placebo. In: Murphy G, Khoury S, Chateliun C, et al., editor. Recent advances in urological cancers and diagnosis and treatment. Paris: SCI, 1990: 61-2
56. Navratil H. Double blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin: results on 49 cases from a multicentre study. In: Murphy S, Khoury P, Kuss C, et al., editors. Prostatic cancer. Part A. New York: Alan R Liss, 1987: 401-10
57. Furr BJA, Valcaccia B, Curry B, et al. [C] 176.334. A novel non-steroidal, peripherally selective antiandrogen. J Endocrinol 1987; 113: R7-9
58. Denis L. Indications for antiandrogen treatment in prostate cancer. In: Denis L, editor. Antiandrogens in prostate cancer. Berlin: Springer-Verlag, 1996: 113-20
59. Verhelst J, Denis L, Van Vliet P, et al. Endocrine profiles during administration of the new non-steroidal antiandrogen Casodex in prostate cancer. Clin Endocrinol 1994; 41 (4): 525-30
60. Kolvenbach GJ, Blackledge GR. Worldwide activity and safety of bicalutamide: a summary review. Urology 1996; 47 Suppl. 1A: 70-9
61. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996; 47 Suppl. 1A: 38-43
62. Kaisary AV, Tyrrell CJ, Beacock C, et al. A randomised comparison of monotherapy with Casode 50 mg daily and castration in the treatment of metastatic prostate cancer: Casodex Study Group. Eur Urol 1995; 28 (3): 215-22
63. Chodak G, Sharifi R, Kasimis B, et al. Single agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate cancer. Urology 1995; 46 (6): 849-55
64. Schellhamer P, Sharifi R, Block N, et al. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flulamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex combination study group. Urology 1996; 47 Suppl. 1A: 54-60
65. Nieh PT. Withdrawal phenomenon with the antiandrogen Casodex. J Urol 1995; 153: 1070-2
66. Liebertz C, Kelly WK, Theodoulou M, et al. High-dose Casodex for prostate cancer (PC): PSA declines in patients with flutamide withdrawal responses. Proc Am Soc Clin Oncol 1995; 14: 232